CY1122760T1 - Τροποποιητης εξενατιδης και χρηση αυτου - Google Patents

Τροποποιητης εξενατιδης και χρηση αυτου

Info

Publication number
CY1122760T1
CY1122760T1 CY20201100184T CY201100184T CY1122760T1 CY 1122760 T1 CY1122760 T1 CY 1122760T1 CY 20201100184 T CY20201100184 T CY 20201100184T CY 201100184 T CY201100184 T CY 201100184T CY 1122760 T1 CY1122760 T1 CY 1122760T1
Authority
CY
Cyprus
Prior art keywords
manufacture
drugs
exenatide
diseases
medicaments
Prior art date
Application number
CY20201100184T
Other languages
English (en)
Inventor
Jiandong Yuan
Yangqing HUANG
Yunsong SONG
Fang Yuan
Original Assignee
Brightgene Bio-Medical Technology Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brightgene Bio-Medical Technology Co., Ltd. filed Critical Brightgene Bio-Medical Technology Co., Ltd.
Publication of CY1122760T1 publication Critical patent/CY1122760T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Αποκαλύπτονται ένας τροποποιητής εξενατίδης για τη σύνδεση της εξενατίδης σε μια λιπαρή αλυσίδα με ένα καρβοξυ στο άκρο αυτής μέσω ενός υδρόφιλου συνδετικού βραχίονα, και μια χρήση αυτού στην παρασκευή φαρμάκων που χρησιμεύουν ως αγωνιστής υποδοχέα GLΡ-1• μια χρήση στην παρασκευή φαρμάκων για την πρόληψη ή/και θεραπευτική αγωγή ασθενειών ή/και συμπτωμάτων που σχετίζονται με χαμηλή δραστικότητα υποδοχέα GLΡ-1• μια χρήση στην παρασκευή φαρμάκων για ασθένειες ή/και συμπτώματα που σχετίζονται με γλυκομεταβολισμό• μια χρήση στην παρασκευή φαρμάκων για διαβήτη• μια χρήση στην παρασκευή φαρμάκων για ασθένεια λιπώδους ήπατος, και χρήση στην παρασκευή φαρμάκων για απώλεια βάρους.
CY20201100184T 2015-09-25 2020-02-28 Τροποποιητης εξενατιδης και χρηση αυτου CY1122760T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510619012.7A CN106554403B (zh) 2015-09-25 2015-09-25 艾塞那肽修饰物及其用途
PCT/CN2016/098844 WO2017050157A1 (zh) 2015-09-25 2016-09-13 艾塞那肽修饰物及其用途

Publications (1)

Publication Number Publication Date
CY1122760T1 true CY1122760T1 (el) 2021-03-12

Family

ID=58385848

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100184T CY1122760T1 (el) 2015-09-25 2020-02-28 Τροποποιητης εξενατιδης και χρηση αυτου

Country Status (18)

Country Link
US (1) US11179467B2 (el)
EP (1) EP3321279B1 (el)
JP (1) JP6647387B2 (el)
KR (1) KR102005294B1 (el)
CN (1) CN106554403B (el)
AU (1) AU2016328015B9 (el)
CA (1) CA2995613C (el)
CY (1) CY1122760T1 (el)
DK (1) DK3321279T3 (el)
ES (1) ES2775185T3 (el)
HR (1) HRP20200332T1 (el)
HU (1) HUE048411T2 (el)
LT (1) LT3321279T (el)
PL (1) PL3321279T3 (el)
PT (1) PT3321279T (el)
RS (1) RS60053B1 (el)
SI (1) SI3321279T1 (el)
WO (1) WO2017050157A1 (el)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111333714A (zh) * 2020-03-05 2020-06-26 成都奥达生物科技有限公司 一种长效glp-1化合物
CN112939771A (zh) * 2021-01-28 2021-06-11 宁夏蓝博思化学技术有限公司 长链烷基二酸单叔丁酯的制备方法
CN115124602B (zh) * 2021-03-25 2024-01-26 博瑞生物医药（苏州）股份有限公司 Gip和glp-1的双受体激动剂、药物组合物及用途
WO2024061310A1 (zh) * 2022-09-23 2024-03-28 博瑞生物医药（苏州）股份有限公司 一种glp-1和gip双受体激动剂药物组合物及其用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003522099A (ja) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
NZ512663A (en) 1999-01-14 2004-05-28 Amylin Pharmaceuticals Inc Novel exendin agonist formulations and methods of administration thereof
TW200522976A (en) 2003-09-19 2005-07-16 Novo Nordisk As Novel plasma protein affinity tags
CN101128214A (zh) * 2005-03-18 2008-02-20 诺和诺德公司 长效glp-1化合物
TWI362392B (en) * 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
CN101125207B (zh) 2006-11-14 2012-09-05 上海华谊生物技术有限公司 带有聚乙二醇基团的艾塞丁或其类似物及其制剂和用途
CN101215324B (zh) 2007-12-26 2010-11-24 吉林大学 艾塞那肽短肽模拟肽及其在制备糖尿病治疗药物中的应用
MX2010008024A (es) 2008-02-01 2010-12-21 Ascendis Pharma As Profarmaco que comprende un enlazador que se puede separar por si mismo.
US20110171164A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of glp-2-like peptides
CN101870728A (zh) 2009-04-23 2010-10-27 派格生物医药(苏州)有限公司 新型Exendin变体及其缀合物
CN102397558B (zh) 2010-09-09 2013-08-14 中国人民解放军军事医学科学院毒物药物研究所 Exendin-4类似物的定位聚乙二醇化修饰物及其用途
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
WO2013059323A1 (en) 2011-10-18 2013-04-25 Prolynx Llc Peg conjugates of exenatide
CN102532303A (zh) 2011-12-22 2012-07-04 江苏弘和药物研发有限公司 聚乙二醇缀合的艾塞那肽的合成及应用
CN102827270A (zh) 2012-09-13 2012-12-19 无锡和邦生物科技有限公司 一种聚乙二醇化艾塞那肽衍生物及其用途
CN103405753B (zh) * 2013-08-13 2016-05-11 上海仁会生物制药股份有限公司 稳定的促胰岛素分泌肽水针药物组合物
KR101768446B1 (ko) * 2014-03-21 2017-08-17 애니젠 주식회사 신규한 엑세나타이드 유사체 및 그의 용도

Also Published As

Publication number Publication date
US20200101162A1 (en) 2020-04-02
DK3321279T3 (da) 2020-03-09
RS60053B1 (sr) 2020-04-30
LT3321279T (lt) 2020-04-10
ES2775185T3 (es) 2020-07-24
WO2017050157A1 (zh) 2017-03-30
PL3321279T3 (pl) 2020-10-19
CN106554403B (zh) 2021-08-31
SI3321279T1 (sl) 2020-07-31
CN106554403A (zh) 2017-04-05
KR20180031740A (ko) 2018-03-28
JP6647387B2 (ja) 2020-02-14
CA2995613A1 (en) 2017-03-30
HUE048411T2 (hu) 2020-07-28
US11179467B2 (en) 2021-11-23
AU2016328015A1 (en) 2018-03-01
AU2016328015B9 (en) 2018-12-06
EP3321279A4 (en) 2018-05-16
EP3321279A1 (en) 2018-05-16
PT3321279T (pt) 2020-03-05
AU2016328015B2 (en) 2018-10-25
HRP20200332T1 (hr) 2020-06-12
KR102005294B1 (ko) 2019-07-30
EP3321279B1 (en) 2020-02-12
CA2995613C (en) 2021-07-20
AU2016328015A9 (en) 2018-11-01
JP2018531217A (ja) 2018-10-25

Similar Documents

Publication Publication Date Title
CY1122760T1 (el) Τροποποιητης εξενατιδης και χρηση αυτου
CY1120030T1 (el) Διπλοι glp1/gip ή τριγωνικοι αγωνιστες glp1/gip/ γλυκαγονης
CY1122466T1 (el) Σκευασμα αντισωματος αντι il-17ra και θεραπευτικα σχηματα για την αγωγη της ψωριασης
CY1123571T1 (el) Βουπροπιονη για τη ρυθμιση των φαρμακευτικων επιπεδων δεξτρομεθορφανης στο πλασμα
UY37505A (es) Conjugados que comprenden un agonista dual de glp-1/glucagón, un conector y ácido hialurónico
CY1121462T1 (el) Ακυλιωμενα αναλογα γλυκαγονης
CY1121203T1 (el) Θεραπευτικες χρησεις της εμπαγλιφλοζινης
CY1125068T1 (el) Ενωσεις τετραϋποκατεστημενου αλκενιου και χρηση αυτων
CY1121735T1 (el) 7-benzyλ-10-(2-meθyλobenzyλ)-2,6,7,8,9,10-eξaϋδpoϊmiδazo[1,2-α]πυριδο[4,3-d]πυριμιδιν-5(3η)-ονη για χρηση στην αγωγη του καρκινου
CY1119577T1 (el) Συν-αγωνιστες υποδοχεα γλυκαγονης/glp-1
BR112018073511A2 (pt) polipeptídeos seletivos do receptor de glucagon e métodos de uso dos mesmos
CY1120939T1 (el) Συνδυασμος ρεγοραφενιμπης και ακετυλοσαλικυλικου οξεος για τη θεραπευτικη αντιμετωπιση του ορθοκολικου καρκινου
BR112016022465A2 (pt) agonistas de receptores de glp-1/glucagon duplo peptídicos derivados de exendina-4
BR112017025108A2 (pt) compostos seletivos de pyy e usos dos mesmos
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
CY1123485T1 (el) Συνθεσεις και μεθοδοι για τη θεραπεια νοσων
EA201890272A1 (ru) Axl-специфические конъюгаты антитело-лекарственное средство для лечения рака
BR112015025464A2 (pt) coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico
BR112017009807A2 (pt) métodos e formulações para tratamento de doenças oculares vasculares
CL2012000092A1 (es) Compuestos derivados de piridina y pirazina o una sal de los mismos, moduladores de proteina quinasa cdk9; composicion farmaceutica que los comprende, util para el tratamiento del cancer, hipotrofia cardiaca, vih y enfermedades inflamatorias.
BR112014014124A2 (pt) Moduladores do receptor de estrogênio fluorados e usos dos mesmos
BR112016022754A2 (pt) derivados de exendina-4 como agonistas peptídicos duplos dos receptores de glp-1 / glucagon
AR092925A1 (es) Derivados de exendina-4 como agonistas duales de glp1 / glucagon
DOP2013000280A (es) Proteínas de unión a antígeno
CO6680687A2 (es) Inmunoglobinas con dominio variable dual capaces de unirse a il 1 beta e il-17, composiciones farmaceúticas y conjugados de proteína de unión de las mismas